Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

VXCO-102

Other · developed by Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company

Phase 1 Most advanced trial
LLY Developer

What is VXCO-102?

VXCO-102 is an investigational drug studied in EBV.

At a glance

Drug type
Other
Therapy area
Infectious disease
Developer
Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

EBV

More from Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind VXCO-102

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.